Sanofi to acquire a 16% stake in Orano Med for €300m.

Sanofi, a French multinational pharmaceutical company, agreed to acquire a 16% stake in Orano Med, a biotechnology company developing cancer therapies, for €300m. “Sanofi’s partnership with Orano Med is a strong recognition of the potential of lead-212 based radioligand therapies to advance the treatment of cancers. This validates our strategy, having developed this expertise over the past 15 years, and reinforces our position as a leader in targeted alpha therapies. We look forward to combining Sanofi’s expertise with our R&D and world-class radiopharmaceutical capabilities to advance the development of potentially transformative therapies like AlphaMedix and make them available to patients in need as quickly as possible,” Julien Dodet, Orano Med President of the Governing Board.